JP5009152B2 - 放射線誘発性腸炎の予防、処置、および回復 - Google Patents

放射線誘発性腸炎の予防、処置、および回復 Download PDF

Info

Publication number
JP5009152B2
JP5009152B2 JP2007515393A JP2007515393A JP5009152B2 JP 5009152 B2 JP5009152 B2 JP 5009152B2 JP 2007515393 A JP2007515393 A JP 2007515393A JP 2007515393 A JP2007515393 A JP 2007515393A JP 5009152 B2 JP5009152 B2 JP 5009152B2
Authority
JP
Japan
Prior art keywords
composition
cancer
administered
balsalazide
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517871A (ja
JP2008517871A5 (https=
Inventor
ダグ ベッテンハウゼン，
クリストファー ジャハラス，
Original Assignee
サリックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリックス ファーマシューティカルズ， インコーポレイテッド filed Critical サリックス ファーマシューティカルズ， インコーポレイテッド
Priority claimed from PCT/US2005/018757 external-priority patent/WO2005117851A1/en
Publication of JP2008517871A publication Critical patent/JP2008517871A/ja
Publication of JP2008517871A5 publication Critical patent/JP2008517871A5/ja
Application granted granted Critical
Publication of JP5009152B2 publication Critical patent/JP5009152B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007515393A 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復 Expired - Fee Related JP5009152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60895104P 2004-05-28 2004-05-28
US60/608,951 2004-10-26
PCT/US2005/018757 WO2005117851A1 (en) 2004-05-28 2005-05-27 Prevention, treatment, and amelioration of radiation induced enteritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011233631A Division JP2012021031A (ja) 2004-10-26 2011-10-25 放射線誘発性腸炎の予防、処置、および回復

Publications (3)

Publication Number Publication Date
JP2008517871A JP2008517871A (ja) 2008-05-29
JP2008517871A5 JP2008517871A5 (https=) 2008-07-10
JP5009152B2 true JP5009152B2 (ja) 2012-08-22

Family

ID=40096437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515393A Expired - Fee Related JP5009152B2 (ja) 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復

Country Status (4)

Country Link
US (3) US20080306029A1 (https=)
JP (1) JP5009152B2 (https=)
KR (1) KR20130028807A (https=)
DE (1) DE602005022175D1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита
CA3259788A1 (en) * 2022-06-22 2023-12-28 Bioventures, Llc METHOD FOR ATTENUATING INJURY BY RADIATION USING GERANYL TRANSFERASE INHIBITORS
CN115252685A (zh) * 2022-06-24 2022-11-01 内蒙古民族大学附属医院 一种蒙药巴特日-7在预防和治疗放射性肠道损伤中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (https=) * 1980-03-20 1982-03-11
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
DE3887353T2 (de) * 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
EP0971735B1 (en) * 1997-04-01 2008-03-19 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
DK1313697T3 (da) * 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
ATE460394T1 (de) * 2000-08-29 2010-03-15 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AU2002318935A1 (en) * 2001-07-31 2003-02-17 The General Hospital Corporation Methods and compositions for treating and preventing distal bowel lesions
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US20060177444A1 (en) * 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復

Also Published As

Publication number Publication date
KR20130028807A (ko) 2013-03-19
US20160120886A1 (en) 2016-05-05
US20080306029A1 (en) 2008-12-11
JP2008517871A (ja) 2008-05-29
US20170333458A1 (en) 2017-11-23
DE602005022175D1 (de) 2010-08-19
HK1099517A1 (en) 2007-08-17

Similar Documents

Publication Publication Date Title
Marshall et al. Treatment of gastrointestinal radiation injury with hyperbaric oxygen
US20170333458A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
Del Rosso et al. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender
Thenarasu et al. Comparison of efficacy of diclofenac and paracetamol as preemptive analgesic agent
AU2005249479B2 (en) Prevention, treatment, and amelioration of radiation induced enteritis
CN108125940B (zh) 戊酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2012021031A (ja) 放射線誘発性腸炎の予防、処置、および回復
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
Santos et al. Multimodal analgesia for postoperative pain in Asia: a review of evidence with clinical focus on dexketoprofen and tramadol/dexketoprofen fixed-dose combination.
CN102225101B (zh) 一种治疗痔疮的中药
ES2348039T3 (es) Prevencion, tratamiento y mejora de la enteritis inducida por radiacion.
AU2011213847A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
HK1099517B (en) Prevention, treatment, and amelioration of radiation induced enteritis
JP2014530249A5 (https=)
Gopal et al. Delayed-onset lumbosacral polyradiculitis following proton precision beam therapy for localized prostate cancer: a case report
Proud The use of oral transmucosal fentanyl citrate during high-dose-rate gynecologic brachytherapy.
CN110279691A (zh) 一种外科术后护理镇痛药物及其用途
CN109419936A (zh) 一种治疗痔疮的内服中药组合物
Economou et al. Chemotherapy of cancer of the alimentary tract
CN109675008B (zh) 防治产后尿潴留症的中药组合物及其制备方法和用途
CN117243948A (zh) 包含瑞香素的组合物在制备风湿性关节炎药物中的应用
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
Sahni et al. Role of hyperbaric oxygen therapy in oncology and radiation induced tissue damage
Horwhat et al. Radiation enteritis
Wiseman et al. Relationship of pelvic radiation to intestinal blood flow

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120502

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120530

R150 Certificate of patent or registration of utility model

Ref document number: 5009152

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150608

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees